US11326210B2ActiveUtilityA1
Compositions and methods for monitoring, diagnosis, prognosis, detection, and treatment of cancer
Est. expiryJan 30, 2035(~8.6 yrs left)· nominal 20-yr term from priority
G01N 33/57595G01N 33/57557C12N 15/113A61K 31/7052C12Q 2600/112C12Q 2600/158A61K 45/06C12Q 1/6886A61P 35/00C12Q 1/6883G01N 2333/4703C12N 2310/11A61P 29/00A61K 31/713G01N 2800/7095C12N 2310/14C12Q 2600/106C12N 2310/141C12N 2320/30G01N 33/57407G01N 33/57496A61K 31/4245C07K 2317/56A61K 31/47
53
PatentIndex Score
0
Cited by
10
References
5
Claims
Abstract
The present invention relates to the field of cancer and inflammation, and in particular methods of monitoring, diagnosis, prognosis, detecting, treating and preventing cancer and inflammation conditions. The use of composition comprises method of monitoring, diagnosis, prognosis, and detecting cancer and inflammation with EN2 and/or SATB2 expression and/or activity. The pharmaceutical composition will further comprise agents that inhibit EN2 and/or SATB2 expression or activity.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1. A method for treating or preventing cancer in a subject, comprising administering to the subject a pharmaceutical composition comprising an effective amount of at least one agent that inhibits at least one of EN2 expression, EN2 transcriptional activity, SATB2 expression, or SATB2 transcriptional activity, wherein
SATB2 and EN2 are highly expressed in the cancer, and
the at least one agent is a small organic molecule represented by a compound having the chemical structure of
2. The method of claim 1 , wherein the at least one agent comprises a targeting moiety capable of binding to a surface of a cancer cell, wherein the targeting moiety is selected from the group consisting of aptamers, peptides, biodegradable materials, antibody-derived epitope binding domains, cellular ligands, and combination thereof.
3. The method of claim 1 , wherein the method further comprises:
determining EN2 and/or SATB2 expression level of said subject.
4. The method of claim 1 , wherein the at least one agent is administered in nanoparticles.
5. The method of claim 1 , wherein the at least one agent is administered to the subject in combination with one or more chemotherapeutic drugs or radiation for treatment and prevention of cancer.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.